Non-cystic fibrosis bronchiectasis

American Journal of Respiratory and Critical Care Medicine

Volumn 188, Issue 6, 2013, Pages 647-656

  McShane, Pamela J ^a   Naureckas, Edward T ^a   Tino, Gregory ^b   Strek, Mary E ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bronchiectasis; Nontuberculous mycobacteria; Pseudomonas aeruginosa; Pulmonary disease

Indexed keywords

ALPHA 1 ANTITRYPSIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; C REACTIVE PROTEIN; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; CORTICOSTEROID; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DORNASE ALFA; ERYTHROMYCIN ETHYLSUCCINATE; FLUTICASONE; FORMOTEROL; GENTAMICIN; IMMUNOGLOBULIN G; MACROLIDE; MANNITOL; PENICILLIN DERIVATIVE; PLACEBO; SODIUM CHLORIDE; TOBRAMYCIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ANAMNESIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ASSISTED VENTILATION; AUTOGENIC DRAINAGE; BACTERIAL COLONIZATION; BREATHING EXERCISE; BRONCHIECTASIS; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CYSTIC FIBROSIS; DIAGNOSTIC TEST; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DYSPNEA; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEART ARRHYTHMIA; HETEROZYGOSITY; HIGH FREQUENCY OSCILLATION; HUMAN; IMMUNOGLOBULIN G DEFICIENCY; IMMUNOMODULATION; KINESIOTHERAPY; LOW DRUG DOSE; LUNG CLEARANCE; LUNG FUNCTION; LUNG TUBERCULOSIS; MORTALITY; MUCUS SECRETION; MULTICENTER STUDY (TOPIC); OSTEOPOROSIS; PATHOGENESIS; POSITIVE END EXPIRATORY PRESSURE; POSITIVE END EXPIRATORY PRESSURE VENTILATOR; POSTURAL DRAINAGE; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; PULMONARY REHABILITATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATION CONTROL; RESPIRATORY THERAPEUTIC DEVICE; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; REVIEW; SPUTUM; SPUTUM CULTURE; THORAX PERCUSSION; THORAX RADIOGRAPHY;

ADRENAL CORTEX HORMONES; AIRWAY MANAGEMENT; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BRONCHI; BRONCHIECTASIS; BRONCHODILATOR AGENTS; EXERCISE THERAPY; HUMANS; MACROLIDES;

EID: 84884623378     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201303-0411CI     Document Type: Review

References (113)

1. Laënnec R T H. On mediate auscultation, or a treatise on the diagnosis of diseases of the lungs and heart. Paris: J.-A. Brosson et J.-S. Chaudé; 1819.
2. McGuinness G, Naidich DP. CT of airways disease and bronchiectasis. Radiol Clin North Am 2002;40:1-19.
3. Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis Non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65:i1-i58.
4. Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots R. Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000 to 2007. Chest 2012;142:432-439.
5. Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005;12:205-209.
6. Onen ZP, Gulbay BE, Sen E, Yildiz OA, Saryal S, Acican T, Karabiyikoglu G. Analysis of the factors related to mortality in patients with bronchiectasis. Respir Med 2007;101:1390-1397.
7. Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, Wilson R. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009;34:843-849.
8. Goeminne PC, Scheers H, Decraene A, Seys S, Dupont LJ. Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients. Respir Res 2012;13:21.
9. Reid LM. Reduction in bronchial subdivision in bronchiectasis. Thorax 1950;5:233-247.
10. Cole PJ. Inflammation: a two-edged sword-the model of bronchiectasis. Eur J Respir Dis Suppl 1986;147:6-15.
11. Gaga M, Bentley AM, Humbert M, Barkans J, O'Brien F, Wathen CG, Kay AB, Durham SR. Increases in CD41 T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax 1998;53:685-691.
12. Matthews LW, Spector S, Lemm J, Potter JL. Studies on pulmonary secretions. I. The over-all chemical composition of pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy. Am Rev Respir Dis 1963;88:199-204.
13. Currie DC, Pavia D, Agnew JE, Lopez-Vidriero MT, Diamond PD, Cole PJ, Clarke SW. Impaired tracheobronchial clearance in bronchiectasis. Thorax 1987;42:126-130.
14. Wills PJ, Garcia Suarez MJ, Rutman A, Wilson R, Cole PJ. The ciliary transportability of sputum is slow on the mucus-depleted bovine trachea. Am J Respir Crit Care Med 1995;151:1255-1258.
15. Moulton BC, Barker AF. Pathogenesis of bronchiectasis. Clin Chest Med 2012;33:211-217.
16. Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, Flower CD, Bilton D, Keogan MT. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000;162:1277-1284.
17. Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med 2007;101:1163-1170.
18. McShane PJ, Naureckas ET, Strek ME. Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture. Chest 2012;142:159-167.
19. Moore EH. Atypical mycobacterial infection in the lung: CT appearance. Radiology 1993;187:777-782.
20. Kartalija M, Ovrutsky AR, Bryan CL, Pott GB, Fantuzzi G, Thomas J, Strand MJ, Bai X, Ramamoorthy P, Rothman MS, et al. Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. Am J Respir Crit Care Med 2013;187:197-205.
21. Chan ED, Iseman MD. Underlying host risk factors for nontuberculous mycobacterial lung disease. Semin Respir Crit Care Med 2013;34:110-123.
22. Paganin F, Séneterre E, Chanez P, Daurés JP, Bruel JM, Michel FB, Bousquet J. Computed tomography of the lungs in asthma: influence of disease severity and etiology. Am J Respir Crit Care Med 1996;153:110-114.
23. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, MacNee W, Miller BE, Rennard S, Silverman EK, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010;11:122.
24. Martínez-García MA, de la Rosa Carrillo D, Soler-Cataluña JJ, Donat-Sanz Y, Serra PC, Lerma MA, Ballestín J, Sánchez IV, Selma Ferrer MJ, Dalfo AR, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:823-831.
25. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med 2006;100:2183-2189.
26. Nicotra MB, Rivera M, Dale AM, Shepherd R, Carter R. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest 1995;108:955-961.
27. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, et al.; Cystic Fibrosis Foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008;153:S4-S14.
28. Bienvenu T, Sermet-Gaudelus I, Burgel PR, Hubert D, Crestani B, Bassinet L, Dusser D, Fajac I. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2010;181:1078-1084.
29. Griffith DE, Aksamit TR. Bronchiectasis and nontuberculous mycobacterial disease. Clin Chest Med 2012;33:283-295.
30. Kim RD, Greenberg DE, Ehrmantraut ME, Guide SV, Ding L, Shea Y, Brown MR, Chernick M, Steagall WK, Glasgow CG, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008;178:1066-1074.
31. Boon M, Jorissen M, Proesmans M, De Boeck K. Primary ciliary dyskinesia, an orphan disease. Eur J Pediatr 2013;172:151-162.
32. Walker WT, Jackson CL, Lackie PM, Hogg C, Lucas JS. Nitric oxide in primary ciliary dyskinesia. Eur Respir J 2012;40:1024-1032.
33. Horváth I, Loukides S, Wodehouse T, Csiszér E, Cole PJ, Kharitonov SA, Barnes PJ. Comparison of exhaled and nasal nitric oxide and exhaled carbon monoxide levels in bronchiectatic patients with and without primary ciliary dyskinesia. Thorax 2003;58:68-72.
34. Henig NR, Tonelli MR, Pier MV, Burns JL, Aitken ML. Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis. Thorax 2001;56:306-311.
35. Boiselle PM, Biederer J, Gefter WB, Lee EY. Expert opinion: why is MRI still an under-utilized modality for evaluating thoracic disorders? J Thorac Imaging 2013;28:137.
36. Montella S, Santamaria F, Salvatore M, Pignata C, Maglione M, Iacotucci P, Mollica C. Assessment of chest high-field magnetic resonance imaging in children and young adults with noncystic fibrosis chronic lung disease: comparison to high-resolution computed tomography and correlation with pulmonary function. Invest Radiol 2009;44:532-538.
37. Puderbach M, Eichinger M, Gahr J, Ley S, Tuengerthal S, Schmähl A, Fink C, Plathow C, Wiebel M, Müller FM, et al. Proton MRI appearance of cystic fibrosis: comparison to CT. Eur Radiol 2007;17:716-724.
38. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Microbiologic follow-up study in adult bronchiectasis. Respir Med 2007;101:1633-1638.
39. Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Cole PJ, Wilson R. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997;10:1754-1760.
40. Davies G, Wells AU, Doffman S, Watanabe S, Wilson R. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur Respir J 2006;28:974-979.
41. Evans SA, Turner SM, Bosch BJ, Hardy CC, Woodhead MA. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur Respir J 1996;9:1601-1604.
42. Seitz AE, Olivier KN, Steiner CA, Montes de Oca R, Holland SM, Prevots DR. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest 2010;138:944-949.
43. Falkinham JO. Impact of human activities on the ecology of nontuberculous mycobacteria. Future Microbiol 2010;5:951-960.
44. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al.; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Diseases Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
45. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002;15:167-193.
46. de Vries SP, Bootsma HJ, Hays JP, Hermans PW. Molecular aspects of Moraxella catarrhalis pathogenesis. Microbiol Mol Biol Rev 2009;73:389-406.
47. Hall-Stoodley L, Keevil CW, Lappin-Scott HM. Mycobacterium fortuitum and Mycobacterium chelonae biofilm formation under high and low nutrient conditions. J Appl Microbiol 1998;85:60S-69S.
48. Otto M. Staphylococcal biofilms. Curr Top Microbiol Immunol 2008;322:207-228.
49. Hall-Stoodley L, Stoodley P. Evolving concepts in biofilm infections. Cell Microbiol 2009;11:1034-1043.
50. Jefferson KK, Goldmann DA, Pier GB. Use of confocal microscopy to analyze the rate of vancomycin penetration through Staphylococcus aureus biofilms. Antimicrob Agents Chemother 2005;49:2467-2473.
51. Atkinson S, Williams P. Quorum sensing and social networking in the microbial world. J R Soc Interface 2009;6:959-978.
52. Gillis RJ, White KG, Choi KH, Wagner VE, Schweizer HP, Iglewski BH. Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2005;49:3858-3867.
53. Lam J, Chan R, Lam K, Costerton JW. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect Immun 1980;28:546-556.
54. Chotirmall SH, O'Donoghue E, Bennett K, Gunaratnam C, O'Neill SJ, McElvaney NG. Sputum Candida albicans presages FEV1 decline and hospital-treated exacerbations in cystic fibrosis. Chest 2010;138:1186-1195.
55. McCool FD, Rosen MJ. Nonpharmacologic airway clearance therapies: ACCP evidence-based clinical practice guidelines. Chest 2006;129:250S-259S.
56. Fink JB. Forced expiratory technique, directed cough, and autogenic drainage. Respir Care 2007;52:1210-1221, discussion 1221-1223.
57. Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J 2009;34:1086-1092.
58. Nicolini A, Cardini F, Landucci N, Lanata S, Ferrari-Bravo M, Barlascini C. Effectiveness of treatment with high-frequency chest wall oscillation in patients with bronchiectasis. BMC Pulm Med 2013;13:21.
59. Eaton T, Young P, Zeng I, Kolbe J. A randomized evaluation of the acute efficacy, acceptability and tolerability of flutter and active cycle of breathing with and without postural drainage in non-cystic fibrosis bronchiectasis. Chron Respir Dis 2007;4:23-30.
60. Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65:i1-i58.
61. Daviskas E, Robinson M, Anderson SD, Bye PT. Osmotic stimuli increase clearance of mucus in patients with mucociliary dysfunction. J Aerosol Med 2002;15:331-341.
62. Shibuya Y, Wills PJ, Cole PJ. Effect of osmolality on mucociliary transportability and rheology of cystic fibrosis and bronchiectasis sputum. Respirology 2003;8:181-185.
63. Nicolson CH, Stirling RG, Borg BM, Button BM, Wilson JW, Holland AE. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med 2012;106:661-667.
64. Reeves EP, Williamson M, O'Neill SJ, Greally P, McElvaney NG. Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med 2011;183:1517-1523.
65. Wills PJ, Wodehouse T, Corkery K, Mallon K, Wilson R, Cole PJ. Short-term recombinant human DNase in bronchiectasis: effect on clinical state and in vitro sputum transportability. Am J Respir Crit Care Med 1996;154:413-417.
66. O'Donnell AE, Barker AF, Ilowite JS, Fick RB; rhDNase Study Group. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. Chest 1998;113:1329-1334.
67. Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care 2007;52:1176-1193, discussion 1193-1197.
68. Riise GC, Larsson S, Larsson P, Jeansson S, Andersson BA. The intrabronchial microbial flora in chronic bronchitis patients: a target for N-acetylcysteine therapy? Eur Respir J 1994;7:94-101.
69. Martínez-García MA, Soler-Cataluña JJ, Perpiñá-Tordera M, Román-Sánchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007;132:1565-1572.
70. Ong HK, Lee AL, Hill CJ, Holland AE, Denehy L. Effects of pulmonary rehabilitation in bronchiectasis: a retrospective study. Chron Respir Dis 2011;8:21-30.
71. Al Moamary MS. Impact of a pulmonary rehabilitation programme on respiratory parameters and health care utilization in patients with chronic lung diseases other than COPD. East Mediterr Health J 2012;18:120-126.
72. Patterson K, Strek ME. Allergic bronchopulmonary aspergillosis. Proc Am Thorac Soc 2010;7:237-244.
73. King P. Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis? Drugs 2007;67:965-974.
74. Elborn JS, Johnston B, Allen F, Clarke J, McGarry J, Varghese G. Inhaled steroids in patients with bronchiectasis. Respir Med 1992;86:121-124.
75. Martínez-García MA, Perpiñá-Tordera M, Román-Sánchez P, Soler-Cataluña JJ. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med 2006;100:1623-1632.
76. Tsang KW, Tan KC, Ho PL, Ooi GC, Ho JC, Mak J, Tipoe GL, Ko C, Yan C, Lam WK, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax 2005;60:239-243.
77. Tsang KW, Ho PL, Lam WK, Ip MS, Chan KN, Ho CS, Ooi CC, Yuen KY. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med 1998;158:723-727.
78. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997;337:8-14.
79. Ip M, Lam K, Yam L, Kung A, Ng M. Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest 1994;105:1722-1727.
80. Martínez-García MA, Soler-Cataluña JJ, Catalán-Serra P, Román-Sánchez P, Tordera MP. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest 2012;141:461-468.
81. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010;23:590-615.
82. Davies G, Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax 2004;59:540-541.
83. Cymbala AA, Edmonds LC, Bauer MA, Jederlinic PJ, May JJ, Victory JM, Amsden GW. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med 2005;4:117-122.
84. Anwar GA, Bourke SC, Afolabi G, Middleton P, Ward C, Rutherford RM. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med 2008;102:1494-1496.
85. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012;380:660-667.
86. Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, van der Werf TS, Boersma WG. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013;309:1251-1259.
87. Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, Biga S, Schlebusch S, Dash P, Bowler SD. Effect of long-term, lowdose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013;309:1260-1267.
88. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics. 2. Advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration 2011;81:75-87.
89. Feldman C. The use of antiinflammatory therapy and macrolides in bronchiectasis. Clin Chest Med 2012;33:371-380.
90. Hughes MG, Evans HL, Chong TW, Smith RL, Raymond DP, Pelletier SJ, Pruett TL, Sawyer RG. Effect of an intensive care unit rotating empiric antibiotic schedule on the development of hospital-acquired infections on the non-intensive care unit ward. Crit Care Med 2004;32:53-60.
91. Gruson D, Hilbert G, Vargas F, Valentino R, Bui N, Pereyre S, Bebear C, Bebear CM, Gbikpi-Benissan G. Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of gram-negative bacilli responsible for ventilator-associated pneumonia. Crit Care Med 2003;31:1908-1914.
92. White L, Mirrani G, Grover M, Rollason J, Malin A, Suntharalingam J. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir Med 2012;106:356-360.
93. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short-and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012;186:657-665.
94. Orriols R, Roig J, Ferrer J, Sampol G, Rosell A, Ferrer A, Vallano A. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med 1999;93:476-480.
95. Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, O'Donnell A, Sahn SA, Smith LJ, Stewart JO, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000;162:481-485.
96. Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005;127:1420-1426.
97. Drobnic ME, Suñé P, Montoro JB, Ferrer A, Orriols R. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005;39:39-44.
98. Dhar R, Anwar GA, Bourke SC, Doherty L, Middleton P, Ward C, Rutherford RM. Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa. Thorax 2010;65:553.
99. Murray MP, Govan JR, Doherty CJ, Simpson AJ, Wilkinson TS, Chalmers JD, Greening AP, Haslett C, Hill AT. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011;183:491-499.
100. Serisier DJ, Bilton D, De Soyza A, Thompson PJ, Kolbe J, Greville HW, Cipolla D, Bruinenberg P, Gonda I; the ORBIT-2 investigators. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebocontrolled trial. Thorax 2013;68:812-817.
101. Chang AB, Bilton D. Exacerbations in cystic fibrosis. 4. Non-cystic fibrosis bronchiectasis. Thorax 2008;63:269-276.
102. Rayner CF, Tillotson G, Cole PJ, Wilson R. Efficacy and safety of longterm ciprofloxacin in the management of severe bronchiectasis. J Antimicrob Chemother 1994;34:149-156.
103. Goldfarb J, Stern RC, Reed MD, Yamashita TS, Myers CM, Blumer JL. Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. Am J Med 1987;82:174-179.
104. Montgomery MJ, Beringer PM, Aminimanizani A, Louie SG, Shapiro BJ, Jelliffe R, Gill MA. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 2001;45:3468-3473.
105. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-2449.
106. Stahlmann R, Lode HM. Risks associated with the therapeutic use of fluoroquinolones. Expert Opin Drug Saf 2013;12:497-505.
107. Bilton D, Henig N, Morrissey B, Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006;130:1503-1510.
108. British Thoracic Society Research Committee. Ceftazidime compared with gentamicin and carbenicillin in patients with cystic fibrosis, pulmonary Pseudomonas infection, and an exacerbation of respiratory symptoms. Thorax 1985;40:358-363.
109. Gold R, Overmeyer A, Knie B, Fleming PC, Levison H. Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis. Pediatr Infect Dis 1985;4:172-177.
110. Murray MP, Turnbull K, Macquarrie S, Hill AT. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J 2009;33:312-318.
111. Weber A, Stammberger U, Inci I, Schmid RA, Dutly A, Weder W. Thoracoscopic lobectomy for benign disease-a single centre study on 64 cases. Eur J Cardiothorac Surg 2001;20:443-448.
112. Zhang P, Zhang F, Jiang S, Jiang G, Zhou X, Ding J, Gao W. Videoassisted thoracic surgery for bronchiectasis. Ann Thorac Surg 2011;91:239-243.
113. Mitchell JD, Yu JA, Bishop A, Weyant MJ, Pomerantz M. Thoracoscopic lobectomy and segmentectomy for infectious lung disease. Ann Thorac Surg 2012;93:1033-1039, discussion 1039-1040.